Ben Hirschler

  • Nearly three years after a cost-cutting drive that stunned many in the drugs industry, Pfizer Inc’s head of research Mikael Dolsten says his scientists are delivering more for less.The ability of the biggest US drugmaker to slash research spending by a fifth without reducing the flow of new ...

    Read More